Zura Bio Limited (ZURA)
| Bid | 1.23 |
| Market Cap | 84.1M |
| Revenue (ttm) | 2K |
| Net Income (ttm) | -47.72M |
| EPS (ttm) | -0.6 |
| PE Ratio (ttm) | -2.05 |
| Forward PE | -1.64 |
| Analyst | Buy |
| Ask | 1.29 |
| Volume | 269,088 |
| Avg. Volume (20D) | 372,329 |
| Open | 1.10 |
| Previous Close | 1.15 |
| Day's Range | 1.14 - 1.25 |
| 52-Week Range | 0.97 - 6.35 |
| Beta | 0.08 |
About ZURA
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California....
Analyst Forecast
According to 7 analyst ratings, the average rating for ZURA stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 1119.51% from the latest price.
Stock Forecasts
1 month ago · businesswire.com
Zura Bio to Present at the Leerink Partners Global Healthcare ConferenceHENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoim...
